AU2018358019B2 - Vaccine T cell enhancer - Google Patents

Vaccine T cell enhancer Download PDF

Info

Publication number
AU2018358019B2
AU2018358019B2 AU2018358019A AU2018358019A AU2018358019B2 AU 2018358019 B2 AU2018358019 B2 AU 2018358019B2 AU 2018358019 A AU2018358019 A AU 2018358019A AU 2018358019 A AU2018358019 A AU 2018358019A AU 2018358019 B2 AU2018358019 B2 AU 2018358019B2
Authority
AU
Australia
Prior art keywords
leu
ser
ala
gln
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018358019A
Other languages
English (en)
Other versions
AU2018358019A1 (en
Inventor
Antonella Folgori
Armin Lahm
Alfredo Nicosia
Elisa Scarselli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nouscom AG
Original Assignee
Nouscom AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom AG filed Critical Nouscom AG
Publication of AU2018358019A1 publication Critical patent/AU2018358019A1/en
Application granted granted Critical
Publication of AU2018358019B2 publication Critical patent/AU2018358019B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2018358019A 2017-11-03 2018-11-02 Vaccine T cell enhancer Active AU2018358019B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17200036.6 2017-11-03
EP17200036 2017-11-03
EP17211235.1 2017-12-29
EP17211235 2017-12-29
PCT/EP2018/080027 WO2019086615A1 (en) 2017-11-03 2018-11-02 Vaccine t cell enhancer

Publications (2)

Publication Number Publication Date
AU2018358019A1 AU2018358019A1 (en) 2020-04-23
AU2018358019B2 true AU2018358019B2 (en) 2023-05-11

Family

ID=64332267

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018358019A Active AU2018358019B2 (en) 2017-11-03 2018-11-02 Vaccine T cell enhancer

Country Status (12)

Country Link
US (1) US11912743B2 (cg-RX-API-DMAC7.html)
EP (1) EP3703744A1 (cg-RX-API-DMAC7.html)
JP (2) JP7386537B2 (cg-RX-API-DMAC7.html)
KR (1) KR102747530B1 (cg-RX-API-DMAC7.html)
CN (1) CN111670046B (cg-RX-API-DMAC7.html)
AU (1) AU2018358019B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008308A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078692A1 (cg-RX-API-DMAC7.html)
IL (1) IL274409B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004552A (cg-RX-API-DMAC7.html)
SG (1) SG11202003799RA (cg-RX-API-DMAC7.html)
WO (1) WO2019086615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12576143B2 (en) * 2018-10-19 2026-03-17 Nouscom Ag Teleost invariant chain cancer vaccine
CN113424264B (zh) * 2018-11-15 2024-04-12 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021209897A1 (en) * 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2022414274A1 (en) * 2021-12-16 2024-08-01 Janssen Biotech, Inc. Prostate cancer vaccines and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082922A1 (en) * 2013-12-04 2015-06-11 Isis Innovation Limited Molecular adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
SI2865387T1 (sl) * 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3190415B1 (en) * 2014-07-25 2019-05-01 Riken Memory invariant nkt cell marker
US20200230220A1 (en) * 2017-07-12 2020-07-23 Nouscom Ag Neoantigen vaccine composition for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082922A1 (en) * 2013-12-04 2015-06-11 Isis Innovation Limited Molecular adjuvant

Also Published As

Publication number Publication date
KR20200076696A (ko) 2020-06-29
RU2020115109A (ru) 2021-12-03
CN111670046B (zh) 2024-11-08
JP7485422B2 (ja) 2024-05-16
RU2020115109A3 (cg-RX-API-DMAC7.html) 2021-12-03
BR112020008308A2 (pt) 2020-11-17
IL274409B1 (en) 2023-07-01
SG11202003799RA (en) 2020-05-28
US20210363201A1 (en) 2021-11-25
US11912743B2 (en) 2024-02-27
JP2023089103A (ja) 2023-06-27
JP2021502076A (ja) 2021-01-28
CN111670046A (zh) 2020-09-15
AU2018358019A1 (en) 2020-04-23
JP7386537B2 (ja) 2023-11-27
NZ763337A (en) 2025-02-28
KR102747530B1 (ko) 2024-12-27
CA3078692A1 (en) 2019-05-09
IL274409B2 (en) 2023-11-01
EP3703744A1 (en) 2020-09-09
IL274409A (en) 2020-06-30
MX2020004552A (es) 2020-10-07
WO2019086615A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
US11912743B2 (en) Compositition and uses of teleost invariant chain to enhance T cell response to a vaccine
AU2019361280B2 (en) Teleost invariant chain cancer vaccine
US8470560B2 (en) CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
CA2928199C (en) POLYTHERAPY FOR CANCER TREATMENT USING A POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST AND/OR AGONIST OF AN IMMUNE CHECKPOINT INHIBITOR
AU2018300051B2 (en) Neoantigen vaccine composition for treatment of cancer
WO2009002418A2 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
CN112930394B (zh) 表达ii类主要组织相容性复合物的癌细胞疫苗和用于产生整合免疫应答的使用方法
AU2010295497B2 (en) Immunological compositions for HIV
CA3109541C (en) Teleost invariant chain cancer vaccine
RU2794196C2 (ru) Усилитель t-клеточного ответа на вакцину
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
AU2015200094A1 (en) Immunological compositions for HIV

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)